1. Home
  2. SPIR vs FHTX Comparison

SPIR vs FHTX Comparison

Compare SPIR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spire Global Inc.

SPIR

Spire Global Inc.

HOLD

Current Price

$21.31

Market Cap

533.0M

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

BUY

Current Price

$4.86

Market Cap

332.2M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
SPIR
FHTX
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
533.0M
332.2M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
SPIR
FHTX
Price
$21.31
$4.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$15.80
$11.50
AVG Volume (30 Days)
2.2M
131.7K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
134.98
25.32
EPS
1.49
N/A
Revenue
$110,451,000.00
$30,909,000.00
Revenue This Year
$11.91
$7.81
Revenue Next Year
$23.34
$17.72
P/E Ratio
$13.78
N/A
Revenue Growth
13.15
36.75
52 Week Low
$6.60
$3.27
52 Week High
$23.59
$6.95

Technical Indicators

Market Signals
Indicator
SPIR
FHTX
Relative Strength Index (RSI) 68.52 46.58
Support Level $8.16 $4.42
Resistance Level N/A $5.85
Average True Range (ATR) 2.19 0.27
MACD 0.60 0.03
Stochastic Oscillator 83.92 57.65

Price Performance

Historical Comparison
SPIR
FHTX

About SPIR Spire Global Inc.

Spire Global Inc provides space-based data, analytics, and space services, offering datasets and insights about Earth to support decision-making. It builds, owns, and operates a constellation of nanosatellites that observe the Earth in real time using radio frequency (RF) technology. Additionally, it offers Space Services solutions that allow customers to deploy and scale their own satellite constellations using its platform, ground station network, manufacturing facilities, and launch partnerships. The company derives revenue from providing data, insights and access to its cloud-based technology platform sold on a subscription basis.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: